The short version of Melanotan II fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-18 and is reviewed periodically as new material appears.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Atmoun in 2019 brokered a deal between Morocco's foreign intelligence agency, Direction générale des études et de la documentation (DGED) and Panzeri and his colleague Francesco Giorgi, whereby the two would each receive €50,000 a year for lobbying on behalf of Morocco. Marie Arena, head of the subcommittee on human rights comes into the Morocco scene, Atmoun invited Arena and Panzeri to Morocco in January 2022. Giorgi reported that he and Panzeri billed Atmoun for ensuring that mentions of Morocco vanished from a Parliament report on human rights violations. Later in 2022 Arena's son, Ugo Lemaire went on a trip to Morocco, paid for by a Moroccan company. Andrea Cozzolino also appears in the Morocco investigation, he was part of the committee investigating Morocco's use of spyware and was chair of the Parliament's Maghreb delegation coordinating the EU interaction with North African countries. Cozzolino and Atmoun met with Morocco's DGED in Warsaw. In September 2022, 4 Brussels MPs – David Leisterh, David Weytsman, Clémentine Barzin, and Gaëtan Van Goidsenhoven – visited the city of Laâyoune in Western Sahara. The Moroccan parliament had invited the MEPs and paid for the entire trip. Western Sahara is a disputed region, which Morocco claims to be its own. However, after the Belgium investigation opened, the MEPs' trip came under greater scrutiny.
=== Pharmacodynamics === Desloratadine is a selective H1-antihistamine which functions as an inverse agonist at the histamine H1 receptor. At very high doses, is also an antagonist at various subtypes of the muscarinic acetylcholine receptors. This effect is not relevant for the drug's action at therapeutic doses.
MECP2 (methyl CpG binding protein 2) is a gene that encodes the protein MECP2. MECP2 appears to be essential for the normal function of nerve cells. The protein seems to be particularly important for mature nerve cells, where it is present in high levels. The MECP2 protein is likely to be involved in turning off ("repressing" or "silencing") several other genes. This prevents the genes from making proteins when they are not needed. Recent work has shown that MECP2 can also activate other genes. The MECP2 gene is located on the long (q) arm of the X chromosome in band 28 ("Xq28"), from base pair 152,808,110 to base pair 152,878,611. MECP2 is an important reader of DNA methylation. Its methyl-CpG-binding (MBD) domain recognizes and binds 5-mC regions. MECP2 is X-linked and subject to X inactivation. MECP2 gene mutations are the cause of most cases of Rett syndrome, a progressive neurologic developmental disorder and one of the most common causes of cognitive disability in females. At least 53 disease-causing mutations in this gene have been discovered.
Sources: en.wikipedia.org
=== Mechanism of action === Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of renal glucose reabsorption (the remaining 10% is done by SGLT1 inhibition). Blocking this transporter causes up to 119 grams of blood glucose per day to be eliminated through the urine, corresponding to 476 kilocalories. Additional water is eliminated by osmotic diuresis, resulting in a lowering of blood pressure. This mechanism is associated with a low risk of hypoglycaemia (too low blood glucose) compared to other types of anti-diabetic drugs such as sulfonylurea derivatives and insulin.
== Works cited == Hudson, Rex A.; Hanratty, Dennis Michael, eds. (1991). Bolivia: a country study. Washington, D.C.: Federal Research Division, Library of Congress. This article incorporates text from this source, which is in the public domain.{{cite encyclopedia}}: CS1 maint: postscript (link)
College of Allied Health Sciences College of Medicine College of Nursing James L. Winkle College of Pharmacy Hoxworth Blood Center Metabolic Diseases Institute Cincinnati Diabetes and Obesity Center UC Cancer Institute UC Neuroscience Institute UC Heart, Lung and Vascular Institute
== Research == Octreotide has also been used off-label for the treatment of severe, refractory diarrhea from other causes. It is used in toxicology for the treatment of prolonged recurrent hypoglycemia after sulfonylurea and possibly meglitinide overdose. It has also been used with varying degrees of success in infants with nesidioblastosis to help decrease insulin hypersecretion. Several clinical trials have demonstrated the effect of octreotide as acute treatment (abortive agent) in cluster headache, where it has been shown that administration of subcutaneous octreotide is effective when compared with placebo. Octreotide has also been investigated in people with pain from chronic pancreatitis. It has been used in the treatment of malignant bowel obstruction. Octreotide may be used in conjunction with midodrine to partially reverse peripheral vasodilation in the hepatorenal syndrome. By increasing systemic vascular resistance, these medications reduce shunting and improve renal perfusion, prolonging survival until definitive treatment with liver transplant. Similarly, octreotide can be used to treat refractory chronic hypotension. While successful treatment has been demonstrated in case reports, larger studies have failed to demonstrate efficacy in treating chylothorax. A small study has shown that octreotide may be effective in the treatment of idiopathic intracranial hypertension.
Sources: en.wikipedia.org
=== Shellworlds === Shellworlds are introduced in Matter, and consist of multilayered levels of concentric spheres in four dimensions held up by countless titanic interior towers. Their extra dimensional characteristics render some products of Culture technology too dangerous to use and yet others ineffective, notably access to hyperspace. About 4000 were built millions of years ago as vast machines intended to cast a forcefield around the whole of the galaxy for unknown purposes; less than half of those remain at the time of Matter, many having been destroyed by a departed species known as the Iln. The species that developed this technology, known as the Veil or the Involucra, are now lost, and many of the remaining shellworlds have become inhabited, often by many different species throughout their varying levels. Many still hold deadly secret defence mechanisms, often leading to great danger for their new inhabitants, giving them one of their other nicknames: Slaughter Worlds.
=== Total bilirubin === Total bilirubin = direct bilirubin + indirect bilirubin Elevation of both alanine aminotransferase (ALT) and bilirubin is more indicative of serious liver injury than is elevation in ALT alone, as postulated in Hy's law that elucidates the relation between the lab test results and drug-induced liver injury
== Biography == Meldal received B.S. and PhD degrees in chemical engineering from Technical University of Denmark (DTU); his PhD work was supervised by Klaus Bock and focused on the synthetic chemistry of carbohydrates. From 1983 to 1988 he was a postdoctoral fellow in organic chemistry, first at the DTU, next at the MRC Laboratory of Molecular Biology at Cambridge University and then at the University of Copenhagen. In 1996 he was appointed assistant professor at DTU. Since 1998 he has led the synthesis group in the Department of Chemistry of the Carlsberg Laboratory. Meldal developed several technological techniques and instruments for peptide synthesis near the start of his career. He developed the multiple-column synthesis used in peptide and organic synthesis instruments, as well as for assembling large split-mix libraries. He first presented the cycloaddition of acetylenes and azides used in peptide and protein conjugations, in polymers and in material sciences. Meldal's group has then showed this reaction to be orthogonal to the majority of functional group chemistries. More recently Meldal has developed an optical encoding technique and has focused on the merger of organic chemistry and peptide chemistry on solid support. He has devised a range of novel methods for the generation of N-acyl iminium ions in which combinatorial libraries of these compounds are generated and screened for substances with activity toward G protein-coupled receptors in cell-based on-bead screening.
==== Elk ivory ==== The ancestors of elk had teeth, also known as elk ivory, that protruded outwards, similar to animals that have tusks. These served as protection from predators, and for asserting dominance during the mating season. These elk once had much smaller antlers compared to the size of modern-day species' antlers. Elk antlers evolved to become bigger and the use of their tusks diminished as antlers grew, thus evolving towards a smaller size over time, making them nothing more than teeth in their mouths. These teeth have the same chemical compound as the ivory found in the highly used and poached elephant tusks, making it another good alternative when it comes to taking ivory as the teeth can be possibly removed without harming the elk themselves. Among Native Americans and First Nations in elk range, primarily within the Great Plains, Rocky Mountains, and Pacific Northwest, elk teeth has major significance when it comes to jewelry. Among women, men wore them as well. Either through bracelets, earrings, and chokers, there was deeper meaning for both men and women within the tribes. For the women, it was believed that it would bring in good luck and good health. As for the men, it was seen that they were a good hunter.
Concetta Hospital is a general hospital based in Kinnigoli, Dakshina Kannada District Karnataka, India. Concetta Hospital, which was started in 1958 with just 12 beds has now grown into a large Hospital having 65 beds with modern equipment and medical facilities available for the patients of the rural area. Sanjivini, an outreach unit of the hospital, provides a variety of health services to the poor and needy people of Kinnigoli and surrounding villages. Services available at Concetta Hospital include:
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.